GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seelos Therapeutics Inc (NAS:SEEL) » Definitions » 6-1 Month Momentum %

Seelos Therapeutics (Seelos Therapeutics) 6-1 Month Momentum % : -91.67% (As of Apr. 29, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Seelos Therapeutics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-29), Seelos Therapeutics's 6-1 Month Momentum % is -91.67%.

The industry rank for Seelos Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

SEEL's 6-1 Month Momentum % is ranked worse than
98.82% of 1519 companies
in the Biotechnology industry
Industry Median: 4.02 vs SEEL: -91.67

Competitive Comparison of Seelos Therapeutics's 6-1 Month Momentum %

For the Biotechnology subindustry, Seelos Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seelos Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seelos Therapeutics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Seelos Therapeutics's 6-1 Month Momentum % falls into.



Seelos Therapeutics  (NAS:SEEL) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Seelos Therapeutics  (NAS:SEEL) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Seelos Therapeutics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Seelos Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Seelos Therapeutics (Seelos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
300 Park Avenue, 2nd Floor, New York, NY, USA, 10022
Seelos Therapeutics Inc is a clinical-stage biotechnology company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders.
Executives
Raj Mehra director, officer: See Remarks C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Michael Joseph Golembiewski officer: Chief Financial Officer 7 TURTLE CT, FLEMINGTON NJ 08822
Daniel J. O'connor director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Margaret Dalesandro director ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Judith Dunn director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Brian Lian director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Robin L Smith director C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Neil Morton officer: SVP, Chief Business Officer C/O APRICUS BIOSCIENCES, INC., 11975 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Richard W Pascoe director, officer: CEO & Secretary C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Sarissa Capital Domestic Fund Lp 10 percent owner 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830